(C) ELISA analysis of VEGF concentrations in the cultured podocytes media treated with or without resveratrol (25M) for 24 hours. attenuate DN Gabapentin via modulating angiogenesis. == Introduction == Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) in the United States, and affects approximately 40% of diabetic patients [1]. DN is also associated with increased cardiovascular mortality [2]. Since it has brought heavy burden to both the patients and the government, the study of its prevention and treatment is one of the top priorities for both endocrinologists and nephrologists all over the world. Currently, the main treatments for DN are glycemic, lipid and blood pressure control, plus renin-angiotensin-aldosterone system (RAAS) blockade, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) [3]. However, there are still a great number of DN patients progressing into ESRD, even after the aggressive uses of these treatments [3,4]. Thus, novel therapeutic methods are required. The involvement of various factors such as hyperglycemia, angiotensin II, advanced glycation end products (AGEs), oxidative stress, transforming growth factor (TGF-), plasminogen activator inhibitor 1 (PAI-1), and connective tissue growth factor (CTGF) in DN has been reported [5]. Recently, there is a growing body of studies showing that angiogenesis may play an important role in the pathogenesis of DN [6]. Newly created renal capillaries have been exhibited in DN patients [7,8]. A potent stimulator of angiogenesis, vascular endothelial growth factor (VEGF) and its type 2 receptor Flk-1 have also been Gabapentin reported to be increased in DN animal models and patients, especially in Rabbit Polyclonal to MBTPS2 the early stages [8,9]. VEGF has also been shown to promote endothelial cell proliferation, migration, and tube formation [10]. VEGF also induces vascular permeability, and this function is mainly mediated by Flk-1 [11,12]. Thus, it is suggested that VEGF may cause increased glomerular permeability and albuminuria in DN [13]. Furthermore, direct inhibition of VEGF or Flk-1 signaling (with neutralizing antibodies or receptor tyrosine kinase inhibitor) could also attenuate DN in both mouse and rat models [14-16]. In addition, other anti-angiogenic reagents, such as tumstatin;endostatin;angiostatin;2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid (NM-3); and vasohibin-1, have also been reported to have therapeutic potentials in DN animal models [17-22]. Angiopoietin 1 (Ang-1), by binding to its receptor Tie-2, stabilizes the attachment of endothelial cells and promotes the maturation of newly created Gabapentin capillaries [23]. In contrast, as a natural antagonist of Ang-1, angiopoietin 2 (Ang-2) competitively inhibits the binding and conversation between Ang-1 and Tie-2, thus loosens the attachment of endothelial cells and synergizes VEGF to promote angiogenesis [24,25]. Ang-1, Ang-2 and Tie-2 have also been shown to play important functions in the maturation of renal blood Gabapentin vessels during kidney development [26]. Up-regulation of Ang-2, associated with decreased Tie-2 expression, has been reported in DN animal models, even though expression of Ang-1 was not altered [17,18,20]. Resveratrol is usually a natural polyphenol extracted from many plants [27]. It has also been shown to alleviate diabetic cardiac dysfunction [28]. Studies have shown that resveratrol potently suppresses VEGF expression and secretion, possibly through the inhibition of hypoxia-induced factor 1 (HIF-1) [29-32]. Resveratrol also inhibits angiogenesis induced by VEGF, mainly through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation [33]. In addition, down-regulation of Flk-1 expression by resveratrol has also been exhibited [34]. Furthermore, it has also been found that resveratrol has anti-angiogenic effect on tumor growth in vivo [35]. In addition, resveratrol is usually highly-orally assimilated and well tolerated by patients [36,37]. On the other hand, silent information regulator 1 (Sirt1) that can be activated by resveratrol, has been shown to have protective effects in diabetes and its complications Gabapentin [38]. As a class iii histone deacetylase, Sirt1 deacetylates many transcriptional factors, such as p53, FOXO, NF-B, PGC-1, LXR, andetc[39], exerting diverse.